| Summary: | Phosphoinositide 3-kinase (PI3K) is the family of lipid kinases participating in vital cellular processes such as cell proliferation, growth, migration, or cytokines production. Due to the high expression of these proteins in many human cells and their involvement in metabolism regulation, normal embryogenesis, or maintaining glucose homeostasis, the inhibition of PI3K (especially the first class which contains four subunits: <i>α</i>, <i>β</i>, <i>γ</i>, <i>δ</i>) is considered to be a promising therapeutic strategy for the treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE) or multiple sclerosis. In this work, we synthesized a library of benzimidazole derivatives of pyrazolo[1,5-<i>a</i>]pyrimidine representing a collection of new, potent, active, and selective inhibitors of PI3K<i>δ</i>, displaying IC<sub>50</sub> values ranging from 1.892 to 0.018 μM. Among all compounds obtained, CPL302415 (<b>6</b>) showed the highest activity (IC<sub>50</sub> value of 18 nM for PI3K<i>δ</i>), good selectivity (for PI3K<i>δ</i> relative to other PI3K isoforms: PI3K<i>α</i>/<i>δ</i> = 79; PI3K<i>β</i>/<i>δ</i> = 1415; PI3K<i>γ</i>/<i>δ</i> = 939), and promising physicochemical properties. As a lead compound synthesized on a relatively large scale, this structure is considered a potential future candidate for clinical trials in SLE treatment.
|
|---|